Acumen Pharmaceuticals
ABOS
61 hedge funds and large institutions have $155M invested in Acumen Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 19 increasing their positions, 16 reducing their positions, and 9 closing their positions.
153% more call options, than puts
Call options by funds: $534K | Put options by funds: $211K
122% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 9
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
22% more funds holding
Funds holding: 50 → 61 (+11)
19% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 16
2.4% more ownership
Funds ownership: 67.92% → 70.32% (+2.4%)
44% less capital invested
Capital invested by funds: $276M → $155M (-$120M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFO
Pathstone Family Office
Englewood,
New Jersey
|
+$1.86M |
| 2 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$1.61M |
| 3 |
Millennium Management
New York
|
+$1.31M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$1.16M |
| 5 |
Two Sigma Investments
New York
|
+$590K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$4.04M |
| 2 |
MCM
Moore Capital Management
New York
|
-$2.66M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$2.09M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.53M |
| 5 |
EGI
EAM Global Investors
Solana Beach,
California
|
-$1.34M |
ABOS Hedge Fund Activity: Q4 2022 in Review
61 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q4 2022, worth a combined $155M — down 44% from $276M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new ABOS positions and 9 closed out — a net gain of 11 holders — while 19 added to existing stakes and 16 trimmed.
The largest buyer was Pathstone Family Office, adding an estimated $1.86M. The largest seller was Commodore Capital, cutting an estimated $4.04M.
- 61 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q4 2022, up from 50 in Q3 2022.
- Funds reported $155M of Acumen Pharmaceuticals stock for Q4 2022, down 44% quarter-over-quarter.
- 20 funds opened new Acumen Pharmaceuticals positions in Q4 2022 and 9 closed out, a net change of +11 holders.
- The largest Acumen Pharmaceuticals buyer in Q4 2022 was Pathstone Family Office, an estimated $1.86M added.
- The largest Acumen Pharmaceuticals seller in Q4 2022 was Commodore Capital, an estimated $4.04M sold.
Based on aggregated 13F filings for Q4 2022.